Dow jumps 500 points as Trump tariff scope narrows to 'dirty 15' trade partners
Mar 24, 2025
Key Points
- The Dow gains 500 points after the Trump administration narrows reciprocal tariffs to roughly 15 nations with trade imbalances, abandoning broader sectoral levies planned for April 2nd.
- 23andMe files for Chapter 11 bankruptcy; co-founder Anne Wojcicki resigns as CEO to bid independently, citing validation of the direct-to-consumer genetic testing market she created 19 years ago.
- A bankruptcy judge could appoint a consumer privacy ombudsman to evaluate whether 23andMe sells customer genetic data to third parties, following precedent from UBiome's 2019 court-approved data sale.
Summary
The Dow gained approximately 500 points Monday after the Trump administration narrowed its reciprocal tariff plans. According to the Wall Street Journal, the administration will focus tariffs on roughly 15 nations with persistent trade imbalances against the US, which Treasury Secretary Scott Bassant calls the "dirty 15." Sectoral tariffs are now unlikely to be announced on April 2nd. The market reaction reflects relief that initial worst-case scenario fears did not materialize. While the measures still represent a shock to global trade, they fall short of the severe economic outcomes investors had been bracing for.
23andMe files for Chapter 11
23andMe filed for Chapter 11 bankruptcy. Co-founder Anne Wojcicki resigned as CEO to position herself as an independent bidder in the auction process. She stated her initial bid was rejected but indicated she intends to bid again.
Wojcicki framed the moment as validation of the direct-to-consumer genetic testing market she created 19 years ago. Over 15 million people have used 23andMe as customers. The company's core asset in a sale is likely its revenue stream of roughly 1,000 customers per week buying tests at $100 each, rather than the genetic data itself, though that distinction matters for privacy.
Other potential bidders have emerged. Nucleus founder Keon submitted an unsolicited bid months ago. Biology and Selene from Loyal have voiced support for bids, citing 23andMe's formative role in the 2010s biotech ecosystem.
Data sale risk
A critical uncertainty hangs over any acquisition regarding what happens to customer genetic data. The Wall Street Journal noted that in bankruptcy cases, a judge can appoint a consumer privacy ombudsman to evaluate whether a bankrupt company should sell customer private information. When UBiome, a lab testing startup, filed for bankruptcy in 2019, the court-appointed ombudsman ultimately recommended approval of a personal data sale.
23andMe stated there will be no changes to how it stores, manages, and protects customer data, and any buyer must comply with applicable law. The company did not, however, explicitly rule out future data sales to third parties, a notable absence given the precedent. Users concerned about data exposure can delete their accounts through the settings menu.